Ir para o conteúdo principal

Onconetix, (NASDAQ: ONCO) — Perfil da empresa, notícias e dados financeiros

Logo de Onconetix,
ONCO Onconetix,
Onconetix, primary media
Perfil da empresa

Onconetix,

Onconetix (NASDAQ:ONCO) is dedicated to pioneering advancements in cancer treatment through its targeted research and development projects. The company focuses on creating innovative therapies aimed at improving patient outcomes and contributing to the global fight against cancer. Onconetix's objectives center around harnessing cutting-edge science and technology to develop treatments that can effectively target and combat various types of cancer at different stages. Their operations span from early-stage research to clinical trials, with a committed team working tirelessly to translate scientific discoveries into real-world applications. Onconetix aims to establish a robust pipeline of oncology products by leveraging partnerships, academic collaborations, and strategic investments to accelerate the development and availability of groundbreaking cancer therapies.

Resumo

Public USParticipação acionária
2018Ano de fundação
12Funcionários
Cincinnati, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
Cincinnati, US

Produtos e/ou serviços de Onconetix,

  • Development of targeted therapies for various cancers focusing on precision medicine.
  • Research on biomarkers for early cancer detection and treatment efficiency monitoring.
  • Creation of a proprietary drug delivery platform to enhance the efficacy of chemotherapy.
  • Partnerships with pharmaceutical companies for the co-development of cancer therapeutics.
  • Provision of genomics profiling services to support personalized medicine.
  • Implementation of artificial intelligence in drug discovery and development processes.

equipe executiva do Onconetix,

  • Karina M. FedaszInterim Chief Financial Officer
  • David Allan WhiteChief Executive Officer
  • Andrew D. SkiboGlobal Head of Biologics Operations
  • Theodore Scott YohoHead of Business Development
  • Ali I. FattomHead of Science & Discovery
  • Jay NewmarkChief Medical Officer

Principais indicadores financeiros

Resultados divulgados pela Onconetix,, em USD.

Cap. de mercado
3,6 mi
Receita (TTM)
645,8 mil
P/L
0.0
LPA (diluído, TTM)
310.4
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Onconetix,
Fim do ano fiscalReceitaResultado operacionalLucro líquido
815,4 mil-6,3 mi-14 mi
2,5 mi-56,5 mi-58,7 mi
58,5 mil-36 mi-37,4 mi
0-13,5 mi-13,4 mi